Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Avantax Advisory Services Inc. raised its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 170.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,179 shares of the biotechnology company’s stock after buying an additional 28,500 shares during the period. Avantax Advisory Services Inc.’s holdings in Seres Therapeutics were worth $38,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Charles Schwab Investment Management Inc. grew its stake in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares in the last quarter. FMR LLC increased its position in shares of Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Providence Wealth Advisors LLC raised its holdings in shares of Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 22,250 shares in the last quarter. State Street Corp lifted its position in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after purchasing an additional 255,014 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Stock Up 3.5 %

Shares of MCRB stock opened at $0.76 on Friday. The stock’s 50-day moving average price is $0.78 and its 200 day moving average price is $0.83. The stock has a market capitalization of $131.68 million, a PE ratio of -3.28 and a beta of 2.19. Seres Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $1.53.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MCRB. Chardan Capital restated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research note on Thursday, March 20th. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Finally, The Goldman Sachs Group lowered their price target on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.